Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 11/20 | 0.56 |
| ▸ | MMP1 | P03956 | 10/20 | 0.56 |
| ▸ | MMP9 | P14780 | 10/20 | 0.56 |
| ▸ | MMP2 | P08253 | 5/20 | 0.56 |
| ▸ | MMP3 | P08254 | 5/20 | 0.56 |
| ▸ | MMP8 | P22894 | 4/20 | 0.56 |
| ▸ | MMP7 | P09237 | 3/20 | 0.56 |
| ▸ | ADAMTS7 | Q9UKP4 | 2/20 | 0.55 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.55 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | MMP14 | P50281 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6372187 | 0.91 | MMP13 (0.60) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL6291016 | 0.91 | MMP13 (0.67) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL6808795 | 0.86 | ADAMTS7 (0.55) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL7250654 | 0.83 | ADAMTS7 (0.71) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL6809688 | 0.83 | ADAMTS7 (0.56) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL6290459 | 0.80 | MMP13 (0.82) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL6294208 | 0.78 | MMP13 (0.61) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL6360526 | 0.78 | MMP13 (0.61) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL6291014 | 0.78 | MMP13 (0.54) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL6289783 | 0.77 | MMP3 (0.61) | MMP13MMP1MMP9MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127498-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2004-07-01 | — | — | US | claimed |
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-07-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | MME, MMP2, MMP9 | MMP13 38/4885MMP1 15/4885MMP9 3/4885 |
| US-20040127498-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | MME, MMP2, MMP9 | MMP13 38/4885MMP1 15/4885MMP9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.